+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology



Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology



Canadian Journal of Cardiology 25(9): 523-526



The myocardial extracellular matrix is believed to be central to the remodelling that takes place following myocardial infarction. The contribution of markers of collagen metabolism to this process remains less well understood. The present study examined the contribution of some of the markers of collagen metabolism in cardiac remodelling, as well as the effect of spironolactone on the remodelling process. To investigate the pathological contribution of markers of collagen metabolism, including matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), type I collagen carboxyterminal telopeptide (ICTP) and procollagen type I carboxyterminal propeptide (PICP), in cardiac remodelling following ischemic cardiomyopathy, and to examine the pharmacoregulatory effects of spironolactone on collagen metabolism. Eighty-six consecutive patients (62 men and 24 women) with chronic heart failure of ischemic etiology (patient group) and 25 age-matched controls were enrolled in the study. The subjects in the patient group were randomly assigned into a spironolactone or nonspironolactone group. Plasma levels of MMP-9, TIMP-1, ICTP and PICP were measured using ELISA and radioimmunoassay techniques. Furthermore, left ventricular diastolic diameter and ejection fraction were assessed using two-dimensional and Doppler echocardiography. The plasma concentrations of MMP-9, TIMP-1 and the MMP-9 to TIMP-1 ratio, as well as ICTP, were significantly increased in the patient group. The PICP to ICTP ratio in the patient group was significantly lower than that in the age-matched control subjects. After a follow-up period of 24 weeks, the PICP to ICTP ratio increased, and MMP-9, TIMP-1 and the MMP-9 to TIMP-1 ratio decreased in the spironolactone subgroup. Biomarkers of collagen degradation were elevated and correlated with depressed heart function; spironolactone may partially reverse the dysregulation in collagen metabolism.

(PDF emailed within 0-6 h: $19.90)

Accession: 056683311

Download citation: RISBibTeXText

PMID: 19746242

DOI: 10.1016/s0828-282x(09)70138-2


Related references

Shock Wave Therapy Improves Cardiac Function in a Model of Chronic Ischemic Heart Failure: Evidence for a Mechanism Involving VEGF Signaling and the Extracellular Matrix. Journal of the American Heart Association 7(20): E010025-E010025, 2018

Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. Journal of Hypertension 31(6): 1239-1244, 2014

Spironolactone improves coronary endothelial function in patients with chronic heart failure. Journal of the American College of Cardiology 43(5 Supplement A): 519A, March 3, 2004

Aldosterone blockade with spironolactone suppresses vascular ACE and improves endothelial function in patients with chronic heart failure. Circulation 100(18 SUPPL ): I 549, Nov 2, 1999

Trimetazidine improves exercise tolerance and left ventricular function in patients with contemporary treatment of chronic ischemic heart failure. European Heart Journal 34(Suppl 1): 807-807, 2013

Effective sleep apnoea treatment improves cardiac function in patients with chronic heart failure. International Journal of Cardiology 168(1): 157-162, 2014

Anti-aldosterone treatment with spironolactone improves survival of patients with chronic congestive heart failure. DMW (Deutsche Medizinische Wochenschrift) 124(34-35): 987-988, Aug 27, 1999

Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. Journal of the American College of Cardiology 39(5): 754-759, March 6, 2002

Tailored treatment of sleep disordered breathing in patients with chronic heart failure improves cardiac function. International Journal of Cardiology 168(4): 4529-4529, 2014

Implantation of a 3 dimensional fibroblast matrix improves left ventricular function and attenuates LV remodeling in acute and chronic ischemic heart failure. 2008

Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal 162(6): 966-972.E10, 2012

A customised cardiac rehabilitation program decreases hospital admissions and improves exercise capacity in elderly patients with chronic heart failure. European Heart Journal 24(Abstract Supplement): 484, August-September, 2003

Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. International Journal of Cardiology 145(3): 438-443, 2011

Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation 20(3): 392-397, 2009

Noninvasive ventilation improves cardiac function in patients with chronic heart failure. Oncotarget 7(31): 48918-48924, 2016